
|Videos|July 9, 2018
Treatment Options and Care for Patients Who Develop Therapy-Related AML
Treatment Options and Care for Patients Who Develop Therapy-Related AML
Advertisement
Case: A 67-Year-Old Man with Therapy-Related AML
- A 67-year-old man who had received CHOP for diffuse large B-cell lymphoma 3 years prior
- PMH: hypertension controlled with amlodipine
- Laboratory results:
- WBC 15 x 109/L
- Serum creatinine 1.5 mg/dL
- Normal LFTs
- LVEF 50%
- Diagnosis: Acute Myeloid Leukemia
- ECOG PS 1
- The patient received liposomal cytarabine and daunorubicin
- His course was complicated by febrile neutropenia
- After induction, <5% marrow blasts, neutrophil count (>1400/µL), platelets 60,000/µL
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































